Nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
=== April === 1 April Biochemists report finishing the complete sequence of the human genome. A study shows that, contrary to widespread belief, body sizes of mammal extinction survivors of the dinosaur-times extinction event were the first to evolutionarily increase, with brain sizes increasing later in the Eocene. 4 April The Intergovernmental Panel on Climate Change (IPCC) releases the third and final part of its Sixth Assessment Report on climate change, warning that greenhouse gas emissions must peak before 2025 at the latest and decline 43% by 2030, in order to likely limit global warming to 1.5 °C (2.7 °F). Researchers announce a new technique for accelerating the development of vaccines and other pharmaceutical products by up to a million times, using much smaller quantities based on DNA nanotechnology. Alzheimer's disease (AD) research progress:A study reports 42 new genes linked to an increased risk of AD. Researchers report a potential primary mechanism of sleep disturbance as an early-stage effect of neurodegenerative diseases. Researchers identify several genes associated with changes in brain structure over lifetime and potential AD therapy-targets (5 Apr).
However, it is also possible to concentrate material from a dilute stream at the head of a chromatographic column and then switch conditions to elute the adsorbed material in conventional isocratic or gradient modes. Therefore, this approach is not unique to displacement chromatography, although the higher loading capacity and less dilution allow greater concentration in displacement mode. A disadvantage of displacement chromatography is that non-idealities always give rise to an overlap zone between each pair of components; this mixed zone must be collected separately for recycle or discard to preserve the purity of the separated materials. The strategy of adding spacer molecules to form zones between the components (sometimes termed "carrier displacement chromatography") has been investigated and can be useful when suitable, readily removable spacers are found. Another disadvantage is that the raw chromatogram, for instance a plot of absorbance or refractive index vs elution volume, can be difficult to interpret for contiguous zones, especially if the displacement train is not fully developed. Documentation and troubleshooting may require additional chemical analysis to establish the distribution of a given component. Another disadvantage is that the time required for regeneration limits throughput. According to John C.
=== Quantum tunneling === These traditional "over the barrier" mechanisms have been challenged in some cases by models and observations of "through the barrier" mechanisms (quantum tunneling). Some enzymes operate with kinetics which are faster than what would be predicted by the classical ΔG‡. In "through the barrier" models, a proton or an electron can tunnel through activation barriers. Quantum tunneling for protons has been observed in tryptamine oxidation by aromatic amine dehydrogenase. Quantum tunneling does not appear to provide a major catalytic advantage, since the tunneling contributions are similar in the catalyzed and the uncatalyzed reactions in solution. However, the tunneling contribution (typically enhancing rate constants by a factor of ~1000 compared to the rate of reaction for the classical 'over the barrier' route) is likely crucial to the viability of biological organisms. This emphasizes the general importance of tunneling reactions in biology. However, as stated above, this does not represent a true catalytic effect, since the same enhancement exists in the corresponding reference reaction in solution. In 1971-1972 the first quantum-mechanical model of enzyme catalysis was formulated. However, this study did not include any representation of the enzyme environment, nor did it provide a relevant potential energy surface. Consequently, it cannot be considered a true quantum mechanical study of enzyme catalysis. Such investigations became feasible only with the development of combined quantum mechanical/molecular mechanical (QM/MM) methods.
Sources: en.wikipedia.org
Malnutrition and being underweight are more common in the elderly than in adults of other ages. If elderly people are healthy and active, the aging process alone does not usually cause malnutrition. However, changes in body composition, organ functions, adequate energy intake and ability to eat or access food are associated with aging, and may contribute to malnutrition. Sadness or depression can play a role, causing changes in appetite, digestion, energy level, weight, and well-being. A study on the relationship between malnutrition and other conditions in the elderly found that malnutrition in the elderly can result from gastrointestinal and endocrine system disorders, loss of taste and smell, decreased appetite and inadequate dietary intake. Poor dental health, ill-fitting dentures, or chewing and swallowing problems can make eating difficult. As a result of these factors, malnutrition is seen to develop more easily in the elderly. Rates of malnutrition tend to increase with age with less than 10 percent of the "young" elderly (up to age 75) malnourished, while 30 to 65 percent of the elderly in home care, long-term care facilities, or acute hospitals are malnourished. Many elderly people require assistance in eating, which may contribute to malnutrition. However, the mortality rate due to undernourishment may be reduced. Because of this, one of the main requirements of elderly care is to provide an adequate diet and all essential nutrients. Providing the different nutrients such as protein and energy keeps even small but consistent weight gain.
== Thiers wall (1844) – Territorial reform (1860) == On the proposal of the politician Adolphe Thiers, after whom it would be named, a fortification was built around Paris from 1841 to 1844 by order of Louis-Philippe I. The king was convinced that defending the territory required preventing the capital from falling into the hands of foreign armies, as had occurred in 1814 during the Battle of Paris. Louis-Philippe thus wanted to encircle the city with fortifications to make it impregnable. With fifty-two gates or posterns, this fortification encompassed the capital and all or part of the surrounding communes. In these areas, residents avoided the octroi taxes imposed on Parisians, which the Wall of the Farmers-General enforced as both an administrative boundary and a fiscal burden.By the decree of February 16, 1859, and the law of June 16, 1859, Napoleon III extended Paris’s territory to the Thiers wall. On January 1, 1860, the city expanded from twelve to twenty districts. It absorbed, fully or partially, some nearby suburban communes. The 11 fully annexed communes, moving from southwest to southeast through the north and east, were: Vaugirard, Grenelle, Auteuil, Passy, Batignolles-Monceau, Montmartre, La Chapelle, La Villette, Belleville, Charonne, and Bercy. The 13 partially annexed communes, following the same directional pattern, were: Issy-les-Moulineaux, Neuilly, Clichy, Saint-Ouen, Aubervilliers, Pantin, Le Pré-Saint-Gervais, Bagnolet, Saint-Mandé, Ivry, Gentilly, Vanves, and Montrouge.
=== Experimental therapies === Phage therapy against P. aeruginosa has been investigated as a possible effective treatment, which can be combined with antibiotics, has no contraindications and minimal adverse effects. Phages are produced as sterile liquid, suitable for intake, applications etc. Phage therapy against ear infections caused by P. aeruginosa was reported in the journal Clinical Otolaryngology in August 2009. As of 2024, research on the topic is ongoing.
Symptomatic coeliac disease (characterised by symptoms related to gluten) can be further categorised into classical and non-classical. Classical coeliac disease, which in the past has also been called typical coeliac disease, is coeliac disease presenting with malnutrition, malabsorption, and diarrhoea. Non-classical coeliac disease, historically referred to as atypical coeliac disease, is when individuals primarily present with symptoms unrelated to malabsorption. Potential coeliac disease refers to those who have positive serology for coeliac disease but no changes in the small intestine. The term latent coeliac disease has been used interchangeably with potential coeliac disease, but has no consistent definition, and its use is therefore discouraged. Sometimes, those with coeliac disease will continue to experience symptoms or signs of the disease despite being on a gluten-free diet. "Slow responders" or "non responsive coeliac disease" (NRCD) is the persistence of symptoms despite exclusion of gluten for 6 to 12 months. Refractory coeliac disease (RCD) is the persistence of malabsorption and damage to the small intestine after at least 12 months of a gluten-free diet. Most people with NRCD do not have RCD; instead, their symptoms are caused by some other factor. There are two types of RCD: type one has histopathological changes similar to those seen in untreated coeliac disease, whereas type two has abnormal histopathological changes not consistent with untreated coeliac disease.
Sources: en.wikipedia.org
=== Hepatic === Glucokinase can be rapidly activated and inactivated in hepatocytes by a novel regulatory protein (glucokinase regulatory protein), which operates to maintain an inactive reserve of GK, which can be made quickly available in response to rising levels of portal vein glucose. GKRP moves between nucleus and cytoplasm of the hepatocytes and may be tethered to the microfilament cytoskeleton. It forms reversible 1:1 complexes with GK, and can move it from the cytoplasm into the nucleus. It acts as a competitive inhibitor with glucose, such that the enzyme activity is reduced to near-zero while bound. GK:GKRP complexes are sequestered in the nucleus while glucose and fructose levels are low. Nuclear sequestration may serve to protect GK from degradation by cytoplasmic proteases. GK can be rapidly released from GKRP in response to rising levels of glucose. Unlike GK in beta cells, GK in hepatocytes is not associated with mitochondria. Fructose in tiny (micromolar) amounts (after phosphorylation by ketohexokinase to fructose-1-phosphate (F1P)) accelerates release of GK from GKRP. This sensitivity to the presence of small amounts of fructose allows GKRP, GK, and ketohexokinase to act as a "fructose sensing system," which signals that a mixed carbohydrate meal is being digested, and accelerates the utilization of glucose. However, fructose 6-phosphate (F6P) potentiates binding of GK by GKRP. F6P decreases phosphorylation of glucose by GK when glycogenolysis or gluconeogenesis are underway. F1P and F6P both bind to the same site on GKRP.
The plan was for existing TA units to recruit over their establishments (aided by an increase in pay for Territorials, the removal of restrictions on promotion, which had hindered recruiting, construction of better-quality barracks and an increase in supper rations) and then form second-line divisions from cadres that could be increased. The total strength of the TA was to be 440,000: the field force of the Territorial Army was to rise from 130,000 to 340,000, organized in 26 divisions, while an additional 100,000 all ranks would form the anti-aircraft section. The forming Second Line formations were given liberty to be numbered and named as they saw fit, with some using related names and numbers from the First World War e.g. the 23rd (Northumbrian) Infantry Division formed in 1939. The immediate response to this announcement was a vast surge in recruiting with 88,000 men enlisted by the end of April. The London Rifle Brigade raised a second battalion in 24 hours. On 26 April, limited conscription was introduced. This resulted in 34,500 twenty-year-old militiamen being conscripted into the regular army, initially to be trained for six months before deployment to the forming second-line units. In parallel, recruits continued to surge into the Territorial Army but there were grave shortages of instructors and equipment. It was envisioned that the duplicating process and recruiting the required numbers of men would take no more than six months.
=== EC 2.10: metal transferases === The category of EC 2.10 includes enzymes that transfer molybdenum or tungsten-containing groups. However, as of 2011, only one enzyme has been added: molybdopterin molybdotransferase. This enzyme is a component of MoCo biosynthesis in Escherichia coli. The reaction it catalyzes is as follows: adenylyl-molybdopterin + molybdate
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.